Health Care · Pharmaceuticals
Johnson & Johnson JNJ
$253.04+3.07 (+1.23%)delayed quote · as of 2026-07-17 20:57 UTC
Market cap
$609.1B
Previous close
$249.97
Volume
7.5M
52-week range
$162.78 – $269.43
Verdictconfidence 96% · high
Growth, Health and Momentum stand out; quality flashes caution.
4 of 5 dimensions score well; quality flashes caution.
Value603/5 checks
Growth1005/5 checks
Quality251/4 checks
Health804/5 checks
Momentum1005/5 checks
Fair-value estimate $723.20 per share (2-stage FCF · individual beta · 10Y Rf 4.6%) — the price sits 65% below it.
Every check behind these scores — with its numbers, source, and evidence link — is in the workspace.
Key ratioslatest filing FY 2025
Value
P/E TTM
28.7
P/E NTM
19.5
EV/EBITDA
18.8
PEG
4.74
FCF yield
3.2%
Growth
Revenue 3y
+5.6%/yr
Revenue YoY
+6.0%
Expected EPS
+46.9%
Quality
Piotroski F
4 / 9
ROIC
ALAN GLOBAL INTELLIGENCE · alanglobalintelligence.comquote as of 2026-07-17 20:57 UTC · fundamentals FY 2025 · SEC EDGAR
Continue with JNJ in ALAN
Full evidence trail, financial statements back a decade, valuation history, charts, and alerts.
For information and research only. Not investment advice. ALAN does not place trades or execute orders. Figures come from the sources shown and can lag the market; verify independently before making decisions. Past performance is not predictive of future results.